Table 3 Thirty-day mortality and hazard ratios for metformin users and non-users among type 2 diabetic patients admitted to ICUs in Northern Denmark
From: Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study
Number | 30-day mortality, % (95% CI) | Crude HR (95% CI) | AdjustedaHR (95% CI) | Propensity score-adjusted HR (95% CI) | |
|---|---|---|---|---|---|
Overall analysis | 7,404 | ||||
Metformin users | 2,408 | 17.7 (16.3-19.3) | 0.68 (0.61-0.75) | 0.82 (0.73-0.91) | 0.84 (0.75-0.94) |
Metformin monotherapy | 1,073 | 17.6 (15.4-20.0) | 0.67 (0.57-0.78) | 0.80 (0.69-0.94) | 0.82 (0.70-0.95) |
Metformin combination therapy | 1,335 | 17.9 (15.9-20.0) | 0.68 (0.59-0.78) | 0.83 (0.71-0.95) | 0.86 (0.75-1.00) |
Metformin non-user | 4,996 | 25.0 (23.9-26.3) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
- Sulfonylurea monotherapy | 872 | 25.5 (22.7-28.5) | NA | NA | NA |
- Insulin monotherapy | 1,337 | 25.2 (22.9-27.6) | NA | NA | NA |
- Other/combination | 239 | 26.4 (21.3-32.5) | NA | NA | NA |
- No pharmacotherapy | 2,548 | 24.7 (23.1-26.4) | NA | NA | NA |
Subcohort with laboratory data | 5,474 | ||||
Metformin users | 1,799 | 18.0 (16.3-19.9) | 0.71 (0.62-0.80) | 0.85 (0.75-0.97) | 0.88 (0.77-1.01) |
Metformin users, adjusted for admission organ dysfunction | 1,799 | 18.0 (16.3-19.9) | 0.71 (0.62-0.80) | 0.88 (0.77-1.00) | NA |
Metformin non-users | 3,675 | 24.4 (23.1, 25.8) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
Propensity score-matched cohort | |||||
Metformin users | 2,192 | 18.2 (16.7-19.9) | 0.87 (0.76-1.00) | 0.88 (0.75-1.02) | 0.85 (0.73-1.00) |
Metformin non-users | 2,192 | 20.9 (19.3-22.7) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (ref.) |
Monotherapy comparison | 1,945 | ||||
Metformin monotherapy | 1,073 | 17.6 (15.4-20.0) | 0.65 (0.54-0.79) | 0.90 (0.73-1.11) | 0.77 (0.63-0.94) |
Sulfonylurea monotherapy | 872 | 25.5 (22.7-28.5) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (ref.) |